icon- folder.gif   Conference Reports for NATAP  
  6th IAS Conference on HIV Pathogenesis
Treatment and Prevention
July 17-20, 2011, Rome
Back grey_arrow_rt.gif
Elvitegravir Once Daily is Non-Inferior to Raltegravir Twice Daily in Treatment-Experienced Patients: 48 Week Results From a Phase 3 Multicenter, Randomized Double-Blind Study
  Reported by Jules Levin
6thIAS Conference on HIV Pathogenesis, Treatment and Prevention 20 July 2011, Rome, Italy
J-M Molina1*, A LaMarca2, J Andrade-Villaneuva3, B Clotet4, N Clumeck5, Y-P Liu6, L Zhong6, N Margot6, A Cheng6, J Szwarcberg6and SL Chuck6 1Hopital Saint Louis and Univ. Paris 7 Diderot, Paris, France; 2Therafirst Medical Center, Ft Lauderdale, FL; 3Hospital Civil de Guadalajara, CUCS, U de G, Guadalajara, Mexico;4Hospital Universitario Germans Trias i Pujol, Barcelona, Spain; 5C.H.U. St. Pierre, Brussels, Belgium; 6Gilead Sciences, Foster City, CA, USA